InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.795 0.05 (2.87%)+
Announcement
Release
14 Oct 2025 9:13AM
Price at Release
$1.745
Full Release
download
Summary
EMVision Medical Devices Limited has successfully executed a CRC-P Grant Agreement with the Commonwealth of Australia, receiving an initial payment of $453,566 from the $3 million grant. This grant supports a collaborative research project to enhance stroke diagnosis and management in regional emergency departments using EMVision's emu™ point-of-care brain scanner. The collaboration includes the Australian Stroke Alliance and other partners to demonstrate the scanner's clinical benefits. The project is currently in the planning phase, with a clinical study set to commence in regional South Australian hospitals. This initiative marks the first clinical use study of the emu™ brain scanner, aiming to validate its diagnostic utility and expedite patient care in underserved rural areas.
Key Points
  • EMVision Medical Devices Limited has executed a Cooperative Research Centres Projects (CRC-P) Grant Agreement with the Commonwealth of Australia.
  • The company received the first payment of $453,566 as part of the $3m grant.
  • The CRC-P grant supports short-term, industry-led collaborative research projects.
  • EMVision will collaborate with the Australian Stroke Alliance, Titan Pre-hospital Innovation, and South Australian Rural Support Service.
  • The project aims to improve stroke diagnosis and management in regional emergency departments.
  • The study leverages EMVision's emu™ point-of-care brain scanner for faster patient management.
  • This is the first clinical use study for the emu™ brain scanner to validate its utility.
  • Planning for the clinical benefit study is underway, with candidate sites in regional South Australian hospitals being identified.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.